The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …

Human epidermal growth factor receptor 2 (HER2) is overexpressed in around 20–30% of
breast cancer tumors. It is associated with a more aggressive disease, higher recurrence …

Background Trastuzumab improves survival in the adjuvant treatment of HER-positive breast
cancer, although combined therapy with anthracycline-based regimens has been …

Breast cancer is the most frequently diagnosed cancer in women and one of the leading
causes of cancer death for women. Worldwide, over 1.3 million cases of invasive breast …

Background The HER2 gene, which encodes the growth factor receptor HER2, is amplified
and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the …

Background Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical
activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy …

HER2 is a validated target in breast cancer therapy. Two drugs are currently approved for
HER2-positive breast cancer: trastuzumab (Herceptin), introduced in 1998, and lapatinib …

Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer
is associated with decreased overall survival. Trastuzumab, a humanized monoclonal …

Background A subcutaneous formulation of pertuzumab and trastuzumab with recombinant
human hyaluronidase in one ready-to-use, fixed-dose combination vial (pertuzumab …

HER2 amplification is seen in up to 20% of breast cancers and is associated with an
aggressive phenotype. Trastuzumab, a monoclonal antibody to HER2, accrues significant …